Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 76, Issue , 2013, Pages 252-256

  Li, Ning ^a   Han, Xiaohong ^a   Yang, Jianliang ^a   Gui, Lin ^a   Song, Yuanyuan ^a   Du, Ping ^a   Shi, Yuankai ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Bioavailability; Pharmacokinetics; Small cell lung cancer (SCLC); Topotecan; UHPLC MS MS

Indexed keywords

TOPOTECAN; UNCLASSIFIED DRUG; XINZE;

ACCURACY; ARTICLE; CHINESE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; HUMAN; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INFUSIONS, INTRAVENOUS; LIMIT OF DETECTION; LUNG NEOPLASMS; MALE; REPRODUCIBILITY OF RESULTS; SMALL CELL LUNG CARCINOMA; TANDEM MASS SPECTROMETRY; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84872745771     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.12.033     Document Type: Article

References (19)

1. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988, 48:1722-1726.
2. Cormio G., Loizzi V., Gissi F., Camporeale A., De Mitri P., Leone L., Putignano G., Selvaggi L. Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur. J. Gynaecol. Oncol. 2011, 32:153-155.
3. Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 2007, 14:195-208.
4. Coronel J., Cetina L., Candelaria M., Gonzalez-Fierro A., Arias D., Cantu D., Duenas-Gonzalez A. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med. Oncol. 2009, 26:210-214.
5. Suzuki H., Hirashima T., Kobayashi M., Sasada S., Okamoto N., Uehara N., Matsuura Y., Tamiya M., Morishita N., Higashiguchi M., Tsumori T., Kawase I. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. J. Chemother. 2011, 23:367-370.
6. Bruce J.N., Fine R.L., Canoll P., Yun J., Kennedy B.C., Rosenfeld S.S., Sands S.A., Surapaneni K., Lai R., Yanes C.L., Bagiella E., DeLaPaz R.L. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 2011, 69:1272-1279. discussion 1279-1280.
7. Schellens J.H., Creemers G.J., Beijnen J.H., Rosing H., de Boer-Dennert M., McDonald M., Davies B., Verweij J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer 1996, 73:1268-1271.
8. Herben V.M., Rosing H., Ten B.H.W., van Zomeren D.M., Batchelor D., Doyle E., Beusenberg F.D., Beijnen J.H., Schellens J.H. Oral topotecan: bioavailability and effect of food co-administration. Br. J. Cancer 1999, 80:1380-1386.
9. Hubbard K.E., Schaiquevich P., Bai F., Fraga C.H., Miller L., Panetta J.C., Stewart C.F. Application of a highly specific and senstive fluorescent HPLC method for topotecan lactone in whole blood. Biomed. Chromatogr. 2009, 23:707-713.
10. Morgan R.J., Synold T., Mamelak A., Lim D., Al-Kadhimi Z., Twardowski P., Leong L., Chow W., Margolin K., Shibata S., Somlo G., Yen Y., Frankel P., Doroshow H.J. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother. Pharmacol. 2010, 66:927-933.
11. Vali A.M., Shafaghi B., Dadashzadeh S. Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 818:205-212.
12. Leggas M., Zhuang Y., Welden J., Self Z., Waters C.M., Stewart C.F. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. J. Pharm. Sci. 2004, 93:2284-2295.
13. Arellano C., Gandia P., Bettuing L., Woodley J., Chatelut E. Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:645-652.
14. Baczek T., Konieczna L., Belka M., Maciejka-Kapuscinska L., Wisniewski J., Niedzwiecki M., Balcerska A., Adamkiewicz-Drozynska E., Wachowiak J. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. J. Pharm. Biomed. Anal. 2012, 70:330-336.
15. Guidance for Industry, Bioanalytical Method Validation, FDA, http://www.fda.gov/cder/guidance.
16. ®), a phase I and pharmacological study in adult patients with solid tumors. Eur. J. Cancer 1998, 34:1030-1035.
17. Beijnen J.H., Smith B.R., Keijer W.J., van Gijn R., Ten B.H.W., Vlasveld L.T., Rodenhuis S., Underberg W.J. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal. 1990, 8:789-794.
18. de Vries N.A., Ouwehand M., Buckle T., Beijnen J.H., van Tellingen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomed. Chromatogr. 2007, 21:1191-1200.
19. Grochow L.B., Rowinsky E.K., Johnson R., Ludeman S., Kaufmann S.H., McCabe F.L., Smith B.R., Hurowitz L., DeLisa A., Donehower R.C., Et A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 1992, 20:706-713.